Prevalence and Characterization of ESR1 Alterations Detected with an Ultra-Sensitive, Liquid-Only CGP Assay in a Large Breast Cancer Cohort
Year: 2025
Type: article
Study design: Observational Study
Abstract: Introduction: ESR1 variants are a key mechanism of acquired resistance to endocrine therapy in advanced breast cancer, particularly after aromatase inhibitor exposure. Recent guidelines and results from SERENA-6 now support liquid biopsy as the preferred method for detecting ESR1 alterations during therapy due to its accessibility and suitability for serial monitoring.
Source: The Journal of Liquid Biopsy
Authors: Lenny K. Hong, Lenny Hong, Ali Aboosaiedi, Tiffany Farmer, Jeff Gaudet, Atri Choksi, Michael Castro, Jason J. Lukas, Gary Palmer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,080
OpenAlex ID: W4416630613